《大行》瑞银看好翰森(03692.HK)及中生制药(01177.HK) 降石药(01093.HK)及先声(02096.HK)盈测

阿斯达克财经
Mar 07, 2025

瑞银发表研报,表示在中国制药行业中对翰森制药(03692.HK) 及中生制药(01177.HK) 看法正面,看好该两家公司的创新药业务发展,产品有望获得商务拓展前期付款或里程碑付款,另一方面石药集团(01093.HK) 和科伦博泰(06990.HK) 等主要销售仿制药的企业,预期由于原型产品降价及新药销量增长未能抵销影响,或导致收入表现持平甚至录得下跌。该行指,大多数中国药企都预计2025年可实现...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10